Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PhI Dose Escalation Study of LAE005+Afuresertib+Nab_Paclitaxel in Advanced Solid Tumors and PhII Study to Evaluate the Safety and Efficacy of LAE005+Afur+Nab_Paclitaxel or LAE005/Afur+Nab-Paclitaxel in Locally Advanced or mTNBC

NCT05390710 is registered in ClinicalTrials.gov with Laekna Limited as lead sponsor.

NCT NCT05390710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05390710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PhI Dose Escalation Study of LAE005+Afuresertib+Nab_Paclitaxel in Advanced Solid Tumors and PhII Study to Evaluate the Safety and Efficacy of LAE005+Afur+Nab_Paclitaxel or LAE005/Afur+Nab-Paclitaxel in Locally Advanced or mTNBC
Lead sponsor
Laekna Limited
Phase
Phase 1
Overall status
Completed
Start date
June 12, 2021
Completion date
December 11, 2023
Enrollment
21 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, tnbc - triple-negative breast cancer